Celsion gets US nod for prostate cancer trial:
This article was originally published in Clinica
Celsion has gained the go-ahead from the US FDA to begin clinical trials of its heat-activated drug treatment for prostate cancer. The therapy combines a focused-heat thermotherapy delivery system with a heat-sensitive liposome that is designed, when activated, to deliver a chemotherapeutic agent to the targeted tumour site. Celsion, of Columbia, Maryland has exclusive worldwide commercial licences to the heat-activated liposome technology, which was invented by Dr David Needham from Duke University in Durham, North Carolina.
You may also be interested in...
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.
When asked about an inspector general report that found hospitals are struggling with tests and resources, and are looking to the federal government to help facilitate more efficient distribution of medical devices to fight the COVID-19 crisis, President Trump attacked the report as a political hit from an Obama holdover.